Assembly Biosciences, Inc.
ASMBHealthcare|Biotechnology|US
$20.42
+0.42 (+2.10%)
Tangible Book / Share
$16.21
Cash / Share
$16.99
Clinical Trials (25)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04398134 A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | P2 | Terminated | 88 | RCT, Double-blind | ABI-H2158, Placebo, Entecavir (ETV) |
| NCT03780543 A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients | Chronic Hepatitis B | P2 | Terminated | 92 | Open-label | standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI) |
| NCT03577171 A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV) | Chronic Hepatitis B | P2 | Completed | 25 | RCT, Double-blind | ABI-H0731, SOC ETV, Placebo Oral Tablet |
| NCT07762027 A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection | Chronic Hepatitis D Infection | P2 | Not Yet Recruiting | 80 | RCT, Open-label | ABI-6250, ABI-6250 |
| NCT03109730 Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B | Chronic Hepatitis B | P1P2 | Completed | 38 | RCT, Double-blind | ABI-H0731, Placebo for ABI-H0731, Entecavir, Tenofovir Disoproxil Fumarate, Pegasys |
| NCT04820686 A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection | Chronic Hepatitis B | P2 | Terminated | 65 | RCT, Open-label | VBR, AB-729, SOC NrtI |
| NCT04454567 A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors | Chronic Hepatitis B | P2 | Terminated | 2 | RCT, Double-blind | ABI-H0731, Placebo, NrtI |
| NCT04781647 A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | P2 | Terminated | 54 | RCT, Open-label | ABI-H0731, ETV, Peg-IFNα |
| NCT03576066 A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection | Chronic Hepatitis B | P2 | Completed | 73 | RCT, Double-blind | ABI-H0731, SOC NUC, Placebo Oral Tablet |
| NCT06740474 A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants | Hepatitis Delta Virus, Hepatitis D | P1 | Completed | 40 | RCT, Double-blind | ABI-6250, Placebo |
| NCT07850999 A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function | Mild Hepatic Imparement | P1 | Not Yet Recruiting | 20 | Open-label | ABI-6250 |
| NCT04083716 A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults | Chronic Hepatitis B | P1 | Completed | 15 | RCT, Open-label | ABI-H2158 Reference Formulation, ABI-H2158 Test Formulation |
| NCT04637139 A Study to Evaluate the Mass Balance Absorption and AME of VBR | Chronic Hepatitis B | P1 | Completed | 6 | Open-label | Vebicorvir (VBR) |
| NCT03923478 ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis | Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate | P1 | Terminated | 15 | RCT, Double-blind | ABI-M201, Placebo |
| NCT03714152 A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B | Chronic Hepatitis B | P1 | Completed | 80 | RCT, Double-blind | ABI-H2158, Placebo for ABI-H2158 |
| NCT06698575 A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes | Recurrent Genital Herpes Simplex Type 2 | P1 | Completed | 103 | RCT, Double-blind | ABI-1179, ABI-1179 Placebo |
| NCT05569941 A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects | Chronic Hepatitis B | P1 | Completed | 54 | RCT, Double-blind | ABI-4334 Tablet, ABI-4334 Placebo |
| NCT06385327 A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes | Recurrent Genital Herpes Simplex Type 2 | P1 | Completed | 115 | RCT, Double-blind | ABI-5366, ABI-5366 Placebo |
| NCT06384131 A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | P1 | Completed | 20 | RCT, Double-blind | ABI-4334, Placebo |
| NCT05414981 A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | P1 | Completed | 31 | RCT, Double-blind | ABI-H3733, Placebo |
| NCT04142762 A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults | Chronic Hepatitis B | P1 | Completed | 80 | Open-label | ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive |
| NCT04271592 A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults | Chronic Hepatitis B | P1 | Completed | 120 | RCT, Double-blind | ABI-H3733 Liquid Oral Dosage Form, ABI-H3733 Solid Oral Dosage Form, Placebo to ABI-H3733 Liquid Oral Dosage Form, Placebo to ABI-H3733 Solid Oral Dosage Form |
| NCT02908191 A Study in Healthy Volunteers and Patients With Chronic Hepatitis B | Chronic Hepatitis B | P1 | Completed | 86 | RCT, Single-blind | ABI-H0731, Placebo for ABI-H0731, Entecavir, Tenofovir disoproxil fumarate, Pegasys, Nucleos(t)ide |
| NCT02234973 Transformation of Indigenous Primary Healthcare Delivery | Type 2 Diabetes Mellitus | Completed | 500 | — | — | |
| NCT07208422 Task-Specific Self-Rehabilitation Training (TASSRET) Trial | Stroke, Stroke Hemorrhagic | N/A | Completed | 50 | RCT, Double-blind | — |